GLP-1 receptor agonists for Parkinson's disease (original) (raw)

GLP-1 and GIP receptor agonists in the treatment of Parkinson’s disease: Translational systematic review and meta-analysis protocol of clinical and preclinical studies

Luciane Lopes

PLOS ONE, 2021

View PDFchevron_right

ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease

Olivier Rascol

Annals of Neurology, 1999

View PDFchevron_right

Attenuated Postprandial GLP-1 Response in Parkinson’s Disease

Phillip Engen

Frontiers in Neuroscience, 2021

View PDFchevron_right

Novel therapeutic strategies in Parkinson’s disease

László Vecsei

European Journal of Clinical Pharmacology, 2009

View PDFchevron_right

A Review of Randomized Pharmacological for in Parkinson’s Patients and Recommendations

Monica Kurtis

Clinical Trials In Parkinson's Disease, 2020

View PDFchevron_right

Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment

Diane DiEuliis

Neurology, 2004

View PDFchevron_right

Central effects of GLP-1 (1)

Juan Camilo Canon Moreno

View PDFchevron_right

GLP-1a: Going beyond Traditional Use

LUCAS FORNARI LAURINDO

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022

View PDFchevron_right

Systematic Review on Parkinson’s Disease Medications, Emphasizing on Three Recently Approved Drugs to Control Parkinson’s Symptoms

Dr Palanisamy Sivanandy

International Journal of Environmental Research and Public Health, 2021

View PDFchevron_right

Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System

Harmonie Etienne

Frontiers in endocrinology, 2014

View PDFchevron_right

Mavoglurant as a treatment for Parkinson's disease

Dmitry Petrov

2014

View PDFchevron_right

Disclosures to the special issue: The vatican conference on neuroprotection in Parkinson's disease volume 28, issue 1, january 2013

F. Stocchi

Movement Disorders, 2013

View PDFchevron_right

Emerging therapies in the pharmacological treatment of Parkinson's disease

Miri Nussbaum

Drugs, 2002

View PDFchevron_right

Neuroprotection trials in Parkinson's disease: Systematic review

Lesly A Pearce

Movement Disorders, 2009

View PDFchevron_right

D-1 and D-2 Agonists in Parkinson's Disease

abraham lieberman

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 1987

View PDFchevron_right

L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease

Osama Elabi

International Journal of Molecular Sciences, 2021

View PDFchevron_right

Neuroprotection in Parkinson's Disease: A Systematic Review of the Preclinical Data

Hubert Pellikaan

The Open Pharmacology Journal, 2012

View PDFchevron_right

Novel pharmacological targets for the treatment of Parkinson's disease

Graham Collingridge

Nature Reviews Drug Discovery, 2006

View PDFchevron_right

Session 3 ?Analyzer Workshop? Evolution of therapeutic strategies in Parkinson?s disease

Mitsutoshi Yamamoto

Journal of Neurology, 2004

View PDFchevron_right

Evaluating drug treatments for Parkinson's disease: how good are the trials?

Robert Hills

Bmj British Medical Journal, 2002

View PDFchevron_right

Selective D-1 dopamine receptor agonist treatment of parkinson's disease

Paolo Barone

Journal of Neural Transmission, 1987

View PDFchevron_right

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

John Dickson

Lancet (London, England), 2017

View PDFchevron_right

Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease

Nicola Brice

Journal of Pharmacology and Experimental Therapeutics

View PDFchevron_right

Parkinson's disease and D1 dopamine receptors

Richard Mailman

Current opinion in investigational drugs (London, England: 2000)

View PDFchevron_right

Summary of the recommendations of the EFNS/MDS‐ES review on therapeutic management of Parkinson's disease

D. Burn

European Journal of Neurology, 2012

View PDFchevron_right

Pharmacotherapy for Parkinson's disease

Jack Chen

Pharmacotherapy, 2007

View PDFchevron_right

Acute administration of GLP-1 receptor agonists induces hypolocomotion but not anxiety in mice

eero vasar

Acta Neuropsychiatrica, 2012

View PDFchevron_right

Letter Adjunctive Therapies in Parkinson JAMA

Anil Gumber

View PDFchevron_right

GDNF in treatment of Parkinson's disease: response to editorial

Mark Stacy

The Lancet Neurology, 2006

View PDFchevron_right

Promising drug targets and associated therapeutic interventions in Parkinson's disease

Dr. Vivek K . Chaturvedi

Neural Regeneration Research

View PDFchevron_right